Pharmaceutical Materials Science and Engineering Laboratory, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, USA.
Bristol-Myers Squibb, 556 Morris Avenue, Summit, NJ 07901, USA.
Int J Pharm. 2024 Apr 10;654:123956. doi: 10.1016/j.ijpharm.2024.123956. Epub 2024 Feb 28.
Tabletability is an outcome of interparticulate bonding area (BA) - bonding strength (BS) interplay, influenced by the mechanical properties, size and shape, surface energetics of the constituent particles, and compaction parameters. Typically, a more plastic active pharmaceutical ingredient (API) exhibits a better tabletability than less plastic APIs due to the formation of a larger BA during tablet compression. Thus, solid forms of an API with greater plasticity are traditionally preferred if other critical pharmaceutical properties are comparable. However, the tabletability flip phenomenon (TFP) suggests that a solid form of an API with poorer tabletability may exhibit better tabletability when formulated with plastic excipients. In this study, we propose another possible mechanism of TFP, wherein softer excipient particles conform to the shape of harder API particles during compaction, leading to a larger BA under certain pressures and, hence, better tabletability. In this scenario, the BA-BS interplay is dominated by BA. Accordingly, TFP should tend to occur when API solid forms are formulated with a soft excipient. We tested this hypothesis by visualizing the deformation of particles in a model compressed tablet by nondestructive micro-computed tomography and by optical microscopy when the particles were separated from the tablet. The results confirmed that soft particles wrapped around hard particles at their interfaces, while an approximately flat contact was formed between two adjacent soft particles. In addition to the direct visual evidence, the BA-dominating mechanism was also supported by the observation that TFP occurred in the p-aminobenzoic acid polymorph system only when mixed with a soft excipient.
可压性是颗粒间结合面积(BA)和结合强度(BS)相互作用的结果,受到组成颗粒的机械性能、大小和形状、表面能量以及压缩参数的影响。通常,由于在片剂压缩过程中形成更大的 BA,更具塑性的活性药物成分(API)比塑性较差的 API 表现出更好的可压性。因此,如果其他关键药物性质相当,传统上优先选择具有更大塑性的 API 固体形式。然而,片剂可压性翻转现象(TFP)表明,具有较差可压性的 API 固体形式在与塑性赋形剂一起配制时可能表现出更好的可压性。在这项研究中,我们提出了 TFP 的另一种可能机制,即较软的赋形剂颗粒在压缩过程中顺应较硬 API 颗粒的形状,从而在一定压力下形成更大的 BA,进而具有更好的可压性。在这种情况下,BA-BS 相互作用由 BA 主导。因此,当 API 固体形式与软赋形剂一起配制时,TFP 可能会倾向于发生。我们通过非破坏性微计算机断层扫描和光学显微镜观察从片剂中分离的颗粒在模型压缩片剂中的变形,验证了这一假设。结果证实,软颗粒在其界面处包裹硬颗粒,而两个相邻软颗粒之间形成近似平坦的接触。除了直接的视觉证据外,BA 主导机制还得到了以下观察结果的支持:仅当与软赋形剂混合时,p-氨基苯甲酸多晶型系统才会出现 TFP。